Gefitinib, a tyrosine kinase inhibitor, has been shown to reduce cell proliferation and tumor growth in breast cancer cell lines or in vivo conditions in xenografted animals with different levels of EGFR or HER2 expression [118]. This evidence concerns the gene EGFR and neoplasm.